Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Gains from Investment Securities (2018 - 2024)

Historic Gains from Investment Securities for Regen BioPharma (RGBP) over the last 7 years, with Q3 2024 value amounting to $19500.0.

  • Regen BioPharma's Gains from Investment Securities rose 10045.76% to $19500.0 in Q3 2024 from the same period last year, while for Sep 2024 it was -$4.3 million, marking a year-over-year decrease of 9914.94%. This contributed to the annual value of -$935962.0 for FY2025, which is 27284.27% down from last year.
  • According to the latest figures from Q3 2024, Regen BioPharma's Gains from Investment Securities is $19500.0, which was up 10045.76% from -$22154.0 recorded in Q2 2024.
  • Over the past 5 years, Regen BioPharma's Gains from Investment Securities peaked at $67.0 million during Q2 2022, and registered a low of -$67.0 million during Q1 2022.
  • For the 5-year period, Regen BioPharma's Gains from Investment Securities averaged around -$308383.8, with its median value being $19625.5 (2022).
  • As far as peak fluctuations go, Regen BioPharma's Gains from Investment Securities skyrocketed by 99996.6% in 2022, and later plummeted by 2167436.08% in 2023.
  • Over the past 5 years, Regen BioPharma's Gains from Investment Securities (Quarter) stood at $1.7 million in 2020, then skyrocketed by 63.3% to $2.8 million in 2021, then decreased by 23.69% to $2.1 million in 2022, then tumbled by 302.95% to -$4.3 million in 2023, then surged by 100.46% to $19500.0 in 2024.
  • Its Gains from Investment Securities stands at $19500.0 for Q3 2024, versus -$22154.0 for Q2 2024 and -$21402.0 for Q1 2024.